At a glance
ClinicalIndex Comparison RecordN/ACompleted· 789 enrolled
Drug / intervention
Rhinovirus +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Probiotic on the Innate and Adaptive Host Response to Rhinovirus (EPIARR)
In Brief
A clinical study evaluating Bifidobacterium lactis Bl-04, Placebo, and 1 other intervention for Common Cold. Completed, enrolled 789 participants across 1 site.
Detailed Summary
The study is designed to assess the effect of ingestion of a probiotic on innate and adaptive host responses to rhinovirus infection.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCommon Cold
CountriesUnited States
CollaboratorsDuPont Nutrition and Health
Timeline
N/ACompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2012
First PostedAug 2012
Primary CompletionJun 2016
TodayJul 2026
First PostedAug 21, 2012
Enrollment StartAug 1, 2012
Primary CompletionJun 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.8 yearsPosted 13.9 years ago
Interventions
Bifidobacterium lactis Bl-04dietary
The study product will be a 2\*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
Placebodietary
Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
Rhinovirusbiological
rhinovirus for experimental challenge